About Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Financial
Human Longevity vs. Other Decacorns
| Company | Valuation | Total Funding | Funding Rounds |
|---|---|---|---|
| Human Longevity | $50B | $369.80M | 5 |
| Theranos | $11B | $1.37B | 10 |
| Neuralink | $4B | $686.24M | 7 |
| Incredible Health | $2B | $99.55M | 4 |
| Oxford Nanopore Technologies | $4.5B | $1.56B | 20 |
| Polygon | $4B | $4.23M | 2 |
| Athletic Greens | $1B | $115.00M | 2 |
| Altos Labs | $3B | $3.00B | 1 |
| MindMaze | $2B | $340.66M | 10 |
| Viridos | $1B | $202.00M | 10 |
| One Medical | $1.7B | $532.07M | 11 |
| Insightec | $3B | $882.90M | 12 |
| Editas Medicine | $0.6B | $931.60M | 7 |
| Adimab | $1B | $45.48M | 8 |
| Synthego | $1B | $459.69M | 9 |
| Foundation Medicine | $0.5B | $96.50M | 4 |
| Carbon Health | $6B | $622.50M | 11 |
| GRAIL | $1.1B | $2.00B | 5 |
| Freenome | $1B | $1.35B | 9 |
| Kallyope | $1B | $487.20M | 6 |
| Commure | $4B | $620.50M | 8 |
| 23andMe | $3.5B | $1.12B | 14 |
| Doctolib | $6B | $815.03M | 9 |
| Schroedinger | $0.8B | $577.22M | 10 |
| Alan | $3B | $751.56M | 8 |
| Pristyn Care | $1B | $177.00M | 5 |
| Cedar | $3B | $419.36M | 6 |
| ATAI Life Sciences | $2.3B | $522.10M | 11 |
| Trusted Health | $3B | $174.80M | 6 |
| Cerebral | $5B | $462.00M | 4 |
| Clipboard Health | $7B | $94.12M | 5 |
| ZnanyLekarz | $5B | - | - |
| SWORD Health | $2B | $453.47M | 11 |
| Cricket Health | $2B | $111.07M | 7 |
| Solugen | $4B | $855.77M | 10 |
| SonderMind | $1B | $183.04M | 6 |
| Livongo | $2.5B | $235.00M | 6 |
| Cue Health | $2.3B | $899.60M | 11 |
| Cityblock | $6B | $891.30M | 9 |
| Pivot Bio | $2B | $616.90M | 7 |
| Everly Health | $10B | - | 1 |
| Virta Health | $9B | $373.00M | 6 |
| FIGS | $3.5B | $75.00M | 7 |
| GreenLight Biosciences | $1.2B | $449.50M | 10 |
| Medable | $2B | $506.64M | 9 |
| InTouch Health | $1B | $49.20M | 6 |
| Athelas | $9B | $150.13M | 5 |
| ClassPass | $18B | $549.24M | 10 |
| Ro | $33B | $1.03B | 8 |
| Modern Health | $4B | $167.40M | 6 |
| Collective Health | $8B | $719.00M | 6 |
| Benchling | $37B | $411.90M | 9 |
| Zocdoc | $14B | $375.94M | 10 |
| Stemcentrx | $26B | $515.53M | 4 |
| Flatiron Health | $21B | $324.95M | 4 |
| Natalist | $6B | $5.00M | 1 |
| Innovaccer | $3B | $379.10M | 7 |
| Alto Pharmacy | $3B | $680.03M | 11 |
| Fitbit | $0.1B | $66.00M | 4 |
| Vicarious Surgical | $1.1B | $230.15M | 7 |
| Twist Bioscience | $0.4B | $553.11M | 10 |
| Ginger | $15B | $222.42M | 11 |
| Calm | $28B | $218.04M | 8 |
| AbCellera Biologics | $5.3B | $886.98M | 11 |
| Ganymed Pharmaceuticals | $1B | $212.70M | 5 |
| Owkin | $3B | $304.10M | 8 |
| Apeel Sciences | $2B | $719.06M | 12 |
| Noom | $15B | $658.92M | 10 |
Growth Trends & Market Impact
Human Longevity may be growing as indicated by several news articles highlighting advancements and developments in the field. One article discusses innovative approaches to improving human longevity, suggesting progress in the industry. Another article from a reputable financial news source details the involvement of venture capital giants in the quest for longevity breakthroughs, which implies significant investment and interest in the sector. Additionally, a health news article reports on a company revolutionizing aging and healthspan, which could be indicative of a growing market and increased demand for longevity solutions.
Investment history
| Round number | date | Post-round evaluation | investors |
|---|---|---|---|
| №1 | 21.08.2024 | $39.80 million dollars |
TVM Capital Healthcare |
| №2 | 07.11.2019 | $30.00 million dollars |
Emerging Technology Partners |
| №3 | 05.04.2016 | $220.00 million dollars |
Illumina Ventures |
| №4 | 04.03.2014 | $80.00 million dollars | |
| №5 | 01.01.2014 | $80.00 million dollars |